|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Mexiletine#Overdosage]] |
| {{Mexiletine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Overdosage==
| |
| | |
| Clinical findings associated with mexiletine overdosage have included [[drowsiness]], [[confusion]], [[nausea]], [[hypotension]], [[sinus bradycardia,]] [[paresthesia]], [[seizures]], [[bundle branch block]], AV heart block, [[asystole]], [[ventricular tachyarrythmia]], including [[ventricular fibrillation]], [[cardiovascular collapse]] and [[coma]]. The lowest known dose in a fatality case was 4.4 g with postmortem serum mexiletine level of 34 to 37 mcg/mL (Jequier P. et. al., Lancet 1976: 1 (7956): 429). Patients have recovered from ingestion of 4 g to 18 g of mexiletine (Frank S. E. et. al., Am J Emerg Med 1991: 9:43-48).
| |
| | |
| There is no specific antidote for mexiletine. Management of mexiletine overdosage includes general supportive measures, close observation and monitoring of vital signs. In addition, the use of pharmacologic interventions (e.g., pressor agents, [[atropine]] or [[anticonvulsants]]) or transvenous cardiac pacing is suggested, depending on the patient’s clinical condition.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MEXILETINE HYDROCHLORIDE CAPSULE [TEVA PHARMACEUTICALS USA INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=693da40b-26d4-40d6-87d1-158e256f40ab | publisher = | date = | accessdate = 3 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Antiarrhythmic agents}}
| |
| | |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |